γδ T cell-based cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Gamma delta (γδ) T cells are recognized for their potential in cancer immunotherapy due to their ability to secrete Th1-type cytokines and exhibit potent cytotoxicity against various cancer cells.
• Existing research highlights the need for effective methods to expand these immune cells for therapeutic applications.

Purpose of the Study:

• To evaluate the safety and anti-tumor effects of Vγ9Vδ2 T cell therapy in patients with various cancers.
• To assess the efficacy of both intravenous and intraperitoneal administration of Vγ9Vδ2 T cells.

Main Methods:

• Development of a large-scale in vitro expansion method for Vγ9Vδ2 T cells using zoledronate and interleukin-2.
• Conducting Phase I clinical trials involving intravenous injection for various cancers and intraperitoneal injection for gastric cancer with malignant ascites.

Main Results:

• Phase I clinical trials for γδ T cell therapy have been initiated, with safety and response data reported for selected cases.
• Initial results from limited patient cohorts suggest promising clinical responses, warranting further investigation.

Conclusions:

• Vγ9Vδ2 T cell therapy represents a promising approach for cancer immunotherapy.
• The established large-scale expansion method and positive early clinical findings support continued research and development of this therapeutic strategy.